NCT04384484 2026-03-24
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT04998669 2026-03-23
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
University of Miami
Phase 2 Recruiting
NCT04970901 2026-03-13
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.
Phase 1 Recruiting
NCT05991388 2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3 Recruiting
NCT05658562 2026-02-13
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Tanabe Pharma Corporation
Phase 1/2 Active not recruiting
NCT05053659 2026-02-12
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05464719 2026-01-12
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05249959 2026-01-05
FIL_COLUMN
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05453396 2025-10-16
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Phase 2 Recruiting
NCT05270057 2025-10-09
LONCA
Medical College of Wisconsin
Phase 1 Active not recruiting
NCT05672251 2025-10-06
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT05971251 2025-10-01
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT05296070 2025-09-30
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
University of Miami
Phase 2 Recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT06977711 2025-08-05
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT05660395 2025-07-16
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Phase 1 Recruiting
NCT05190705 2025-05-23
Loncastuximab Tesirine in WM
Dana-Farber Cancer Institute
Phase 2 Recruiting